This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

DARA BioSciences To Present Company Update At 2012 BIO Convention

DARA BioSciences, Inc. (Nasdaq: DARA) announced today that Dr. David J. Drutz, Chief Executive Officer, will provide a comprehensive update on the company’s products and pipeline at the 2012 BIO International Convention in Boston later this month. DARA's presentation is part of the BIO Business Forum and is scheduled for 3:45 p.m. ET on Wednesday, June 20, Red Sox Room at the Boston Convention and Exhibition Center. DARA BioSciences focuses on oncology treatment and supportive care products.

Dr. Drutz will discuss the development and commercialization of DARA’s product portfolio, which includes Bionect ®, a topical treatment for skin irritation and burns associated with radiation therapy, introduced to the market June 6, 2012; Soltamox ®, the first and only oral liquid formulation of tamoxifen, widely used in the treatment and prevention of breast cancer, on track for launch in 2012; and KRN5500, under development for the treatment of neuropathic pain in patients with cancer, a condition with no current adequate therapy.

Attendees will be able to arrange one-on-one meetings with DARA in advance through the conference website 2012 BIO International Convention at http://convention.bio.org/.

The BIO International Convention is hosted by the Biotechnology Industry Organization (BIO) and is the preeminent biotechnology meeting worldwide. Presenters at the BIO Business Forum will share breakthroughs in medicine, diagnostics, the environment, energy production, business operations, financing, partnerships, policy issues and food and agriculture.

About DARA BioSciences, Inc.

DARA is a specialty pharmaceutical company focused on the development and commercialization of oncology treatment and supportive care products. DARA sharpened its focus in oncology through its January 2012 acquisition of Oncogenerix, Inc., which holds the exclusive U.S. marketing rights to Soltamox ®. Soltamox ® is a novel oral liquid formulation of tamoxifen, a product used widely in the treatment and prevention of breast cancer. Soltamox ® is the only FDA approved oral liquid version of tamoxifen and fulfills a vital clinical need for patients who cannot tolerate existing tablet formulations of this drug. DARA plans to begin marketing Soltamox ® in the U.S. in the third quarter of 2012.

DARA has also obtained exclusive U.S. commercial rights from Innocutis Holdings, LLC for Bionect ® (hyaluronic acid sodium salt, 0.2%) within the oncology and radiation oncology marketplace. Bionect is an FDA-cleared product indicated for the management of irritation of the skin as well as first and second degree burns. Bionect is currently being promoted and sold by Innocutis in the dermatology market. DARA launched this product in Q2 2012.

DARA has obtained, in addition, the U.S. rights to gemcitabine, a widely used generic chemotherapeutic cancer drug, from Uman Pharma. The Abbreviated New Drug Application (ANDA) for gemcitabine is expected to be filed with the FDA later this year.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,034.93 +208.63 1.17%
S&P 500 2,100.40 +19.22 0.92%
NASDAQ 4,994.6020 +62.7870 1.27%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs